198 related articles for article (PubMed ID: 31527070)
1. Direct Detection and Quantification of Neoantigens.
Wang Q; Douglass J; Hwang MS; Hsiue EH; Mog BJ; Zhang M; Papadopoulos N; Kinzler KW; Zhou S; Vogelstein B
Cancer Immunol Res; 2019 Nov; 7(11):1748-1754. PubMed ID: 31527070
[TBL] [Abstract][Full Text] [Related]
2. Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.
Gloger A; Ritz D; Fugmann T; Neri D
Cancer Immunol Immunother; 2016 Nov; 65(11):1377-1393. PubMed ID: 27600516
[TBL] [Abstract][Full Text] [Related]
3. Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens.
Bassani-Sternberg M
Methods Mol Biol; 2018; 1719():209-221. PubMed ID: 29476514
[TBL] [Abstract][Full Text] [Related]
4. What do cancer-specific CD8+ T cells see? The contribution of immunopeptidomics.
Nicholas B; Skipp P
Essays Biochem; 2023 Sep; 67(6):957-965. PubMed ID: 37503576
[TBL] [Abstract][Full Text] [Related]
5. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.
Rajasagi M; Shukla SA; Fritsch EF; Keskin DB; DeLuca D; Carmona E; Zhang W; Sougnez C; Cibulskis K; Sidney J; Stevenson K; Ritz J; Neuberg D; Brusic V; Gabriel S; Lander ES; Getz G; Hacohen N; Wu CJ
Blood; 2014 Jul; 124(3):453-62. PubMed ID: 24891321
[TBL] [Abstract][Full Text] [Related]
6. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.
Bassani-Sternberg M; Pletscher-Frankild S; Jensen LJ; Mann M
Mol Cell Proteomics; 2015 Mar; 14(3):658-73. PubMed ID: 25576301
[TBL] [Abstract][Full Text] [Related]
7. Identification of Tumor Antigens in the HLA Peptidome of Patient-derived Xenograft Tumors in Mouse.
Rijensky NM; Blondheim Shraga NR; Barnea E; Peled N; Rosenbaum E; Popovtzer A; Stemmer SM; Livoff A; Shlapobersky M; Moskovits N; Perry D; Rubin E; Haviv I; Admon A
Mol Cell Proteomics; 2020 Aug; 19(8):1360-1374. PubMed ID: 32451349
[TBL] [Abstract][Full Text] [Related]
8. Translating Immunopeptidomics to Immunotherapy-Decision-Making for Patient and Personalized Target Selection.
Fritsche J; Rakitsch B; Hoffgaard F; Römer M; Schuster H; Kowalewski DJ; Priemer M; Stos-Zweifel V; Hörzer H; Satelli A; Sonntag A; Goldfinger V; Song C; Mahr A; Ott M; Schoor O; Weinschenk T
Proteomics; 2018 Jun; 18(12):e1700284. PubMed ID: 29505699
[TBL] [Abstract][Full Text] [Related]
9. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.
Freudenmann LK; Marcu A; Stevanović S
Immunology; 2018 Jul; 154(3):331-345. PubMed ID: 29658117
[TBL] [Abstract][Full Text] [Related]
10. Epitope discovery in West Nile virus infection: Identification and immune recognition of viral epitopes.
McMurtrey CP; Lelic A; Piazza P; Chakrabarti AK; Yablonsky EJ; Wahl A; Bardet W; Eckerd A; Cook RL; Hess R; Buchli R; Loeb M; Rinaldo CR; Bramson J; Hildebrand WH
Proc Natl Acad Sci U S A; 2008 Feb; 105(8):2981-6. PubMed ID: 18299564
[TBL] [Abstract][Full Text] [Related]
11. Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes.
Kumari S; Wälchli S; Fallang LE; Yang W; Lund-Johansen F; Schumacher TN; Olweus J
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):403-8. PubMed ID: 24344295
[TBL] [Abstract][Full Text] [Related]
12. High immunogenicity of the human leukocyte antigen peptidomes of melanoma tumor cells.
Jarmalavicius S; Welte Y; Walden P
J Biol Chem; 2012 Sep; 287(40):33401-11. PubMed ID: 22869377
[TBL] [Abstract][Full Text] [Related]
13. HLA class I restricted epitopes prediction of common tumor antigens in white and East Asian populations: Implication on antigen selection for cancer vaccine design.
Hu W; He M; Li L
PLoS One; 2020; 15(2):e0229327. PubMed ID: 32106223
[TBL] [Abstract][Full Text] [Related]
14. Identifying Antigens Recognized by Cytolytic T Lymphocytes on Tumors.
Vigneron N; Stroobant V; Ma W; Michaux A; Van den Eynde BJ
Methods Mol Biol; 2019; 1988():159-186. PubMed ID: 31147940
[TBL] [Abstract][Full Text] [Related]
15. Learning from the Proteasome How To Fine-Tune Cancer Immunotherapy.
Vigneron N; Abi Habib J; Van den Eynde BJ
Trends Cancer; 2017 Oct; 3(10):726-741. PubMed ID: 28958390
[TBL] [Abstract][Full Text] [Related]
16. A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.
Jaigirdar A; Rosenberg SA; Parkhurst M
J Immunother; 2016 Apr; 39(3):105-16. PubMed ID: 26938944
[TBL] [Abstract][Full Text] [Related]
17. Low HLA binding of diabetes-associated CD8+ T-cell epitopes is increased by post translational modifications.
Sidney J; Vela JL; Friedrich D; Kolla R; von Herrath M; Wesley JD; Sette A
BMC Immunol; 2018 Mar; 19(1):12. PubMed ID: 29562882
[TBL] [Abstract][Full Text] [Related]
18. Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1.
Chaux P; Luiten R; Demotte N; Vantomme V; Stroobant V; Traversari C; Russo V; Schultz E; Cornelis GR; Boon T; van der Bruggen P
J Immunol; 1999 Sep; 163(5):2928-36. PubMed ID: 10453041
[TBL] [Abstract][Full Text] [Related]
19. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
20. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
